Concepedia
Statistics
Publications
18
Citations
3.4K
H-Index
16
Active since
1999
Affiliations
Janssen (United States)(Current)
Janssen (Belgium)
Heidelberg University
Millennium Engineering and Integration (United States)
Princess Margaret Cancer Centre
Christopher Enny is an author at Janssen (United States) specializing in medicine, pharmacotherapy, and bortezomib therapy.
Publications per year
1999–2022
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.
B Coiffier, E.A. Osmanov, Xin Hong et al. · The Lancet Oncology · 2011 · 1.6K citations
Medicine, Hematology, Pharmacotherapy +13
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
Martin Dreyling, Wojciech Jurczak, Mats Jerkeman et al. · The Lancet · 2015 · 462 citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial
Howard L. Corwin, Andrew Gettinger, Robert M. Rodriguez et al. · Critical Care Medicine · 1999 · 351 citations
Medicine, Hematology, Pharmacology +15
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
Donna Reece, Ute Hegenbart, Vaishali Sanchorawala et al. · Blood · 2011 · 170 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +8
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
Fritz Offner, Olga Samoilova, Evgenii A. Osmanov et al. · Blood · 2015 · 135 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +7
1–5 of 18